Clinical Trials

39 articles in this category (Page 2 of 2)

Stock Weather AIBiotechClinical Trials

Olema Pharmaceuticals – 2025-12-10 - Increase Confidence 7/10

Negative free cash flow offset by strong cash reserves and recent clinical momentum suggests near-term upside potential.

Dec 10, 2025OLMA

Stock Weather AIBiotechnologyClinical Trials

Structure Therapeutics – 2025-12-08 - Increase Confidence 9/10

Negative free cash flow offset by strong trial data and cash runway, triggering near-term upside momentum.

Dec 8, 2025GPCR

Stock Weather AIBiotechnologyClinical Trials

Terns Pharmaceuticals – 2025-12-08 - increase Confidence 8/10

Strong cash runway into 2028 meets breakthrough Phase 1 data showing 75% MMR in CML, fueling near-term upside for TERN.

Dec 8, 2025TERN

Stock Weather AIBiotechnologyClinical Trials

Praxis Precision Medicines – 2025-12-05 - Increase Confidence 8/10

Negative free cash flow offset by $567M capital raise and positive Phase 3 data for ulixacaltamide drive near-term upside potential.

Dec 5, 2025PRAX

Stock Weather AIBiotechnologyClinical Trials

Spyre Therapeutics – 2025-12-04 - Increase Confidence 7/10

Strong cash infusion from recent offering combined with first patient enrollment in Phase 2 SKYWAY trial signals near-term momentum, supporting stock price increase.

Dec 4, 2025SYRE

Stock Weather AIBiotechClinical Trials

Vera Therapeutics (VERA) – 2025-11-28 - Increase Confidence 6/10

Negative free cash flow and high debt weigh on fundamentals, but recent 8% price surge on positive trial sentiment signals near-term momentum for VERA.

Nov 28, 2025VERA

Stock Weather AIBiotechnologyClinical Trials

Belite Bio – 2025-11-26 - increase Confidence 6/10

Negative free cash flow contrasts with imminent Q3 2025 business update, creating event-driven upside potential for BLTE in the short term.

Nov 26, 2025BLTE

Stock Weather AIBiotechnologyClinical Trials

Jyong Biotech Ltd. – 2025-11-26 - increase Confidence 7/10

Negative free cash flow contrasts with imminent Phase II trial data readout for MCS-8, creating catalyst-driven upside potential in the near term.

Nov 26, 2025MENS

Stock Weather AIBiotechnologyClinical Trials

Structure Therapeutics – 2025-11-18 - Increase Confidence 8/10

Negative free cash flow persists, but $799M cash runway and imminent Phase 2b obesity data create high-impact catalyst for stock upside.

Nov 18, 2025GPCR

Stock Weather AIBiotechnologyClinical Trials

Jazz Pharmaceuticals – 2025-11-18 - Increase Confidence 9/10

Strong free cash flow and record-breaking Phase 3 trial success for Ziihera drive near-term upside potential.

Nov 18, 2025JAZZ

Stock Weather AIBiotechnologyClinical Trials

Jyong Biotech Ltd. – 2025-11-18 - increase Confidence 6/10

Negative free cash flow contrasts with imminent Phase II trial data readout for MCS-8, creating near-term catalyst-driven upside potential.

Nov 18, 2025MENS

Stock Weather AIBiotechnologyClinical Trials

Nuvalent – 2025-11-18 - Increase Confidence 8/10

Negative free cash flow contrasts with strong clinical trial results and FDA engagement plans, fueling near-term upside potential.

Nov 18, 2025NUVL

Stock Weather AIBiotechClinical Trials

Jyong Biotech – 2025-11-17 - increase Confidence 7/10

Negative free cash flow contrasts with imminent Phase II trial data readout for MCS-8, a catalyst likely to drive near-term upside.

Nov 17, 2025MENS

Stock Weather AIBiotechnologyClinical Trials

Nuvalent, Inc. – 2025-11-17 - Increase Confidence 8/10

Strong clinical data catalysts combined with negative free cash flow signal near-term upside driven by sentiment, not fundamentals.

Nov 17, 2025NUVL

Stock Weather AIBiotechnologyClinical Trials

Scholar Rock Holding – 2025-11-14 - Increase Confidence 7/10

Negative free cash flow offset by strong cash runway and imminent regulatory filings for Apitegromab, driving near-term upside potential.

Nov 14, 2025SRRK